Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Control Bionics Ltd. ( (AU:CBL) ) has shared an update.
Control Bionics Limited announced a partnership with Apple’s Brain-Computer Interface (BCI) Protocol, marking a significant step in its commercial strategy and future growth. This collaboration is expected to enhance the company’s market positioning and expand its technological capabilities, potentially impacting stakeholders positively by opening new avenues for growth and innovation.
More about Control Bionics Ltd.
Control Bionics Limited is an Australian company specializing in Electromyography (EMG) medical device technology, aimed at assisting patients with communication challenges due to conditions like Motor Neurone Disease (MND) and Amyotrophic Lateral Sclerosis (ALS). The company offers products such as the NeuroNode, a wireless device that captures brain signals for communication, and is expanding into new markets with its NeuroStrip technology.
Average Trading Volume: 321,339
Technical Sentiment Signal: Hold
Current Market Cap: A$14.14M
Find detailed analytics on CBL stock on TipRanks’ Stock Analysis page.